百奧賽圖-B(02315.HK)與Ona達成協定用於針對實體瘤ADC開發
百奧賽圖-B(02315.HK)公布,與西班牙生物技術公司Ona Therapeutics達成抗體評估、選擇與授權協定。
根據協定,百奧賽圖將授權Ona評估由百奧賽圖專有RenMice(R)平台針對一個特定腫瘤靶點產生的全人抗體。Ona在完成評估後有權獲得其所選定的抗體分子在雙方同意的適應症及地域進行抗體藥物偶聯物的開發、生產和商業化的獨家權益。
Ona行使選擇權後,百奧賽圖將收到預付款;並獲得選擇權執行費、開發和商業化里程碑付款,以及個位數淨銷售額分成。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.